Join
Live feed
·
PRReleasevia Quantisnow
BioNTech SE logo

BioNTech and OncoC4 Present Updated Data Showing Gotistobart Nearly Doubled Median Overall Survival versus Standard-of-Care Chemotherapy in Previously Treated Squamous Non-Small Cell Lung Cancer Patients

ByQuantisnow·Wall Street's wire, on your screen.
BNTX· BioNTech SE
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track BNTX (BioNTech SE) and more on Quantisnow.